{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T06:40:10Z","timestamp":1740120010800,"version":"3.37.3"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1038\/s41386-019-0495-4","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T13:02:42Z","timestamp":1566651762000},"page":"2277-2284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Lessons learned by giving amphetamine to antipsychotic-medicated schizophrenia patients"],"prefix":"10.1038","volume":"44","author":[{"given":"Neal R.","family":"Swerdlow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5560-8011","authenticated-orcid":false,"given":"Savita G.","family":"Bhakta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Talledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"Benster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Kotz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Lavadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Light","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"issue":"Sep 28","key":"495_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/1991271a0","volume":"199","author":"AJ Friedhoff","year":"1963","unstructured":"Friedhoff AJ, VanWinkle E. Conversion of dopamine to 3,4-Dimethoxyphenylacetic acid in schizophrenia patients. Nature. 1963;199(Sep 28):1271\u20132.","journal-title":"Nature"},{"key":"495_CR2","first-page":"492","volume":"160","author":"JM van Rossum","year":"1966","unstructured":"van Rossum JM. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharm Ther. 1966;160:492\u20134.","journal-title":"Arch Int Pharm Ther"},{"key":"495_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1176\/ajp.130.1.61","volume":"130","author":"SH Snyder","year":"1973","unstructured":"Snyder SH. Amphetamine psychosis: a \u201cmodel\u201d schizophrenia mediated by catecholamines. Am J Psychiatry. 1973;130:61\u20137.","journal-title":"Am J Psychiatry"},{"key":"495_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/archpsyc.1973.04200020023003","volume":"29","author":"J Stevens","year":"1973","unstructured":"Stevens J. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973;29:177\u201389.","journal-title":"Arch Gen Psychiatry"},{"key":"495_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr Bull. 2009;35:549\u201362.","journal-title":"Schizophr Bull"},{"key":"495_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.schres.2011.05.004","volume":"130","author":"NR Swerdlow","year":"2011","unstructured":"Swerdlow NR. Are we studying and treating schizophrenia correctly? Schizophr Res. 2011;130:1\u201310.","journal-title":"Schizophr Res"},{"key":"495_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/s41591-018-0021-y","volume":"24","author":"G Ursini","year":"2018","unstructured":"Ursini G, Punzi G, Chen Q, Marenco S, Robinson JF, Porcelli A, et al. Convergence of placenta biology and genetic risk for schizophrenia. Nat Med. 2018;24:792\u2013801.","journal-title":"Nat Med"},{"key":"495_CR8","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1126\/science.3854","volume":"192","author":"I Creese","year":"1976","unstructured":"Creese I, Burt DR, Snyder SH. Dopamine receptors and average clinical doses. Science. 1976;192:481\u20133.","journal-title":"Science"},{"key":"495_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/0269881116636120","volume":"30","author":"RR Girgis","year":"2016","unstructured":"Girgis RR, Van Snellenberg JX, Glass A, Kegeles LS, Thompson JL, Wall M, et al. A proof-of-concept, randomized controlled trial of DAR-0100A, a dopamine-1 receptor agonist, for cognitive enhancement in schizophrenia. J Psychopharmacol. 2016;30:428\u201335.","journal-title":"J Psychopharmacol"},{"key":"495_CR10","doi-asserted-by":"crossref","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421\u20137","DOI":"10.1038\/nature13595"},{"issue":"May-Jun","key":"495_CR11","first-page":"193","volume":"75","author":"A Randrup","year":"1972","unstructured":"Randrup A, Munkvad I. Influence of amphetamines on animal behaviour: stereotypy, functional impairment and possible animal-human correlations. Psychiatr Neurol Neurochir. 1972;75(May-Jun):193\u2013202.","journal-title":"Psychiatr Neurol Neurochir"},{"key":"495_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0278-5846(97)00098-5","volume":"22","author":"SM Antelman","year":"1998","unstructured":"Antelman SM, Gershon S. Clinical application of time-dependent sensitization to antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:65\u201378.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"495_CR13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/bmj.2.4641.1394","volume":"2","author":"GG Wallis","year":"1949","unstructured":"Wallis GG, McHarg JF, Scott OC. Acute psychosis caused by dextro-amphetamine. Br Med J. 1949;2:1394.","journal-title":"Br Med J"},{"key":"495_CR14","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1056\/NEJMoa1813751","volume":"380","author":"LV Moran","year":"2019","unstructured":"Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med. 2019;380:1128\u201338.","journal-title":"N Engl J Med"},{"key":"495_CR15","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/schbul\/sbx021.182","volume":"43","author":"NR Swerdlow","year":"2017","unstructured":"Swerdlow NR, Tarasenko M, Bhakta SG, Talledo J, Alvarez AI, Hughes EL, et al. Amphetamine enhances gains in auditory discrimination training in adult schizophrenia patients. Schizophr Bull. 2017;43:872\u201380.","journal-title":"Schizophr Bull"},{"key":"495_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201376.","journal-title":"Schizophr Bull"},{"key":"495_CR17","volume-title":"The scale for the assessment of negative symptoms (SANS)","author":"NC Andreasen","year":"1984","unstructured":"Andreasen NC. The scale for the assessment of negative symptoms (SANS). Iowa City, IA: University of Iowa; 1984a."},{"key":"495_CR18","volume-title":"The scale for the assessment of positive symptoms (SAPS)","author":"NC Andreasen","year":"1984","unstructured":"Andreasen NC. The scale for the assessment of positive symptoms (SAPS). Iowa City, IA: University of Iowa; 1984b."},{"key":"495_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799\u2013812.","journal-title":"Psychol Rep"},{"key":"495_CR20","doi-asserted-by":"crossref","unstructured":"Rapaport MH, Bazetta J, McAdams LA, Patterson J, Jeste DV. Validation of the scale of functioning in older outpatients with schizophrenia. Am J Geriatr Psychiatry. 1996;4:218\u201328.","DOI":"10.1097\/00019442-199622430-00005"},{"key":"495_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0033-3182(95)71666-8","volume":"36","author":"RC Hall","year":"1995","unstructured":"Hall RC. Global assessment of functioning. A modified scale. Psychosomatics. 1995;36:267\u201375.","journal-title":"Psychosomatics"},{"key":"495_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1176\/appi.ajp.2007.07010042","volume":"165","author":"KH Nuechterlein","year":"2008","unstructured":"Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203\u201313.","journal-title":"Am J Psychiatry"},{"key":"495_CR23","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/npp.2017.285","volume":"43","author":"NR Swerdlow","year":"2018","unstructured":"Swerdlow NR, Bhakta SG, Talledo JA, Franz DM, Hughes EL, Rana BK, et al. Effects of amphetamine on sensorimotor gating and neurocognition in antipsychotic-medicated schizophrenia patients. Neuropsychopharmacology. 2018a;43:708\u201317.","journal-title":"Neuropsychopharmacology"},{"key":"495_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1017\/S0033291700045803","volume":"4","author":"AJ Bond","year":"1974","unstructured":"Bond AJ, James DC, Lader MH. Physiological and psychological measures in anxious patients. Psychol Med. 1974;4:364\u201373.","journal-title":"Psychol Med"},{"key":"495_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0028-3908(71)90039-6","volume":"10","author":"H Norris","year":"1971","unstructured":"Norris H. The action of sedation on brain-stem oculomotor systems in man. Neuropharmacology. 1971;10:181\u201391.","journal-title":"Neuropharmacology"},{"issue":"May","key":"495_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00213-002-1040-3","volume":"161","author":"NR Swerdlow","year":"2002","unstructured":"Swerdlow NR, Eastvold A, Karban B, Ploum Y, Stephany N, Geyer MA, et al. Dopamine agonist effects on startle and sensorimotor gating in normal male subjects: time course studies. Psychopharmacol (Berl). 2002;161(May):189\u2013201.","journal-title":"Psychopharmacol (Berl)"},{"key":"495_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.schres.2013.11.013","volume":"152","author":"TG van Erp","year":"2014","unstructured":"van Erp TG, Preda A, Nguyen D, Faziola L, Turner J, Bustillo J, et al. Converting positive and negative symptom scores between PANSS and SAPS\/SANS. Schizophr Res. 2014;152:289\u201394.","journal-title":"Schizophr Res"},{"key":"495_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.1965.03090040019006","volume":"193","author":"W Modell","year":"1965","unstructured":"Modell W, Hussar AE. Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients: clinical and pharmacological significance. JAMA. 1965;193:275\u20138.","journal-title":"JAMA"},{"key":"495_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.schres.2004.12.019","volume":"77","author":"DM Barch","year":"2005","unstructured":"Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and in healthy volunteers. Schizophr Res. 2005;77:43\u201358.","journal-title":"Schizophr Res"},{"key":"495_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1176\/ajp.148.1.78","volume":"148","author":"TE Goldberg","year":"1991","unstructured":"Goldberg TE, Bigelow LB, Weinberger DR. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry. 1991;148:78\u201384.","journal-title":"Am J Psychiatry"},{"key":"495_CR31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/hup.1118","volume":"25","author":"RH Pietrzak","year":"2010","unstructured":"Pietrzak RH, Snyder PJ, Maruff P. Use of an acute challenge with d-amphetamine to model cognitive improvement in chronic schizophrenia. Hum Psychopharmacol. 2010;25:353\u20138.","journal-title":"Hum Psychopharmacol"},{"issue":"Jul","key":"495_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.schres.2013.03.019","volume":"147","author":"JP Lindenmayer","year":"2013","unstructured":"Lindenmayer JP, Nasrallah H, Pucci M, James S, Citrome L. A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities. Schizophr Res. 2013;147(Jul):241\u201352.","journal-title":"Schizophr Res"},{"key":"495_CR33","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/npp.2013.111","volume":"38","author":"RA Lasser","year":"2013","unstructured":"Lasser RA, Dirks B, Nasrallah H, Kirsch C, Gao J, Pucci ML, et al. Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases. Neuropsychopharmacology. 2013;38:2140\u20139.","journal-title":"Neuropsychopharmacology"},{"key":"495_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00433802","volume":"72","author":"B Angrist","year":"1980","unstructured":"Angrist B, Rotrosen J, Gershon S. Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia. Psychopharmacol (Berl). 1980;72:17\u20139.","journal-title":"Psychopharmacol (Berl)"},{"issue":"Aug","key":"495_CR35","first-page":"991","volume":"139","author":"DP van Kammen","year":"1982","unstructured":"van Kammen DP, Bunney WE Jr, Docherty JP, Marder SR, Ebert MH, Rosenblatt JE, et al. d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. Am J Psychiatry. 1982;139(Aug):991\u20137.","journal-title":"Am J Psychiatry"},{"key":"495_CR36","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1523\/JNEUROSCI.17-07-02551.1997","volume":"17","author":"DS Segal","year":"1997","unstructured":"Segal DS, Kuczenski R. An escalating dose \u201cbinge\u201d model of amphetamine psychosis: behavioral and neurochemical characteristics. J Neurosci. 1997;17:2551\u201366.","journal-title":"J Neurosci"},{"key":"495_CR37","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.biopsych.2008.12.007","volume":"65","author":"A Abi-Dargham","year":"2009","unstructured":"Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. Baseline and amphetamine-stimulated dopamine activity are related in drug-na\u00efve schizophrenic subjects. Biol Psychiatry. 2009;65:1091\u201393.","journal-title":"Biol Psychiatry"},{"key":"495_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/sj.mp.4002066","volume":"13","author":"HA Nasrallah","year":"2008","unstructured":"Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13:27\u201335.","journal-title":"Mol Psychiatry"},{"key":"495_CR39","doi-asserted-by":"publisher","unstructured":"Swerdlow NR, Franz DM, Benster L, Talledo J, Bhakta SG, Light GA. Early Auditory Information Processing in Schizophrenia as a Therapeutic Target: Preliminary Dose-Response Findings With Amphetamine. Proc Am Coll Neuropsychopharmacology 57th Annual Meeting 2018b, 6 December 2018. \nhttps:\/\/doi.org\/10.1038\/s41386-018-0268-5\n\n.","DOI":"10.1038\/s41386-018-0268-5"},{"key":"495_CR40","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: L Erlbaum Assoc.; 1988.","edition":"2nd ed"},{"key":"495_CR41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/npp.2015.162","volume":"41","author":"NR Swerdlow","year":"2016","unstructured":"Swerdlow NR, Bhakta S, Chou HH, Talledo JA, Balvaneda B, Light GA. Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis. Neuropsychopharmacol. 2016;41:419\u201330.","journal-title":"Neuropsychopharmacol"},{"key":"495_CR42","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1093\/ijnp\/pyx074","volume":"20","author":"SG Bhakta","year":"2017","unstructured":"Bhakta SG, Light GA, Talledo JA, Balvaneda B, Hughes E, Alvarez A, et al. Tolcapone-enhanced neurocognition in healthy adults: neural basis and predictors. Int J Neuropsychopharmacol. 2017;20:979\u201387.","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0495-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0495-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0495-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:07:08Z","timestamp":1684616828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-019-0495-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":42,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["495"],"URL":"https:\/\/doi.org\/10.1038\/s41386-019-0495-4","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"type":"print","value":"0893-133X"},{"type":"electronic","value":"1740-634X"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"assertion":[{"value":"23 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}